WFA
NMTR

Wipfli Financial Advisors’s 9 Meters Biopharma NMTR Stock Holding History

Wipfli Financial Advisors’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1K Buy
+225
New +$1.11K ﹤0.01% 2542

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Wipfli Financial Advisors's NMTR Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in 9 Meters Biopharma (NMTR) in Q3 2022: 225 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2542 among its holdings.

74 funds tracked by Wall St. Rank hold NMTR as of Q3 2022.

  • Wipfli Financial Advisors held 225 shares of 9 Meters Biopharma worth $1K as of Q3 2022.
  • 9 Meters Biopharma was a new Wipfli Financial Advisors position in Q3 2022.
  • 9 Meters Biopharma made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2542 holding.
  • 74 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.